<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Hyperkalemia</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->3/12/2010</div></div><div class="card__content"><h1 id="hyperkalemia">Hyperkalemia</h1>
<h2 id="potassium-regulation">Potassium regulation</h2>
<ul>
<li><strong>Internal K shift:</strong> modulated by insulin, catecholamines, acid-base status</li>
<li><strong>Total body K elimination:</strong> By kidney (95%) and gut (5%)</li>
</ul>
<h2 id="adverse-effects-of-hyperkalemia">Adverse effects of hyperkalemia</h2>
<ul>
<li><strong>Cardiac:</strong> Peaked T, wide QRS, loss of P wave, sine wave; although ventricular fibrillation may be first cardiac manifestation</li>
<li><strong>Neuromuscular:</strong> Paresthesias,weakness</li>
<li><strong>Metabolic:</strong> Mild hyperchloremic metabolic acidosis</li>
</ul>
<h2 id="treatment-of-hyperkalemia">Treatment of hyperkalemia</h2>
<p><strong>Mechanism: Cardiac membrane stabilization</strong></p>
<ul>
<li><strong>Calcium:</strong> Reduces threshold potential in myocytes; check to be sure not on digoxin</li>
<li><strong>Hypertonic saline:</strong> Only for severe hyponatremia in setting of hyperkalemia</li>
</ul>
<p><strong>Mechanism: K redistribution</strong></p>
<ul>
<li><strong>Insulin:</strong> Drives K intracellularly and drops serum K level by 0.6 mmol/L</li>
<li><strong>Beta-agonist:</strong> Drives K intracellularly and 10 mg albuterol drops serum K level by 0.6 mmol/L (20 mg --&gt; K drops by 1 mmol/L); effective in only 60% of patients</li>
</ul>
<p><strong>Mechanism: K elimination via kidney/gut</strong></p>
<ul>
<li><strong>Bicarbonate:</strong> drives K out at distal nephron; best as infusion x 4-6 hrs</li>
<li><strong>Loop diuretic</strong></li>
<li><strong>Exchange resin</strong> (sodium polystyrene sulfonate): Of minimal to no benefit. <ul>
<li>Case reports of colonic necrosis </li>
</ul>
</li>
</ul>
<table>
  <tr>
    <th>Agent</th>
    <th>Dose</th>
    <th>Onset</th>
    <th>Duration</th>
    <th>Complication</th>
  </tr>
  <tr>
    <td colspan="5"><b>MEMBRANE STABILIZATION</b></td>
  </tr>
  <tr>
    <td><span class="drug">Ca gluconate 10%</span></td>
    <td>10 mL over 10 min</td>
    <td>Immediate</td>
    <td>30-60 min</td>
    <td>Hypercalcemia</td>
  </tr>
  <tr>
    <td><span class="drug">Hypertonic 3% NaCl</span></td>
    <td>50 mL IV push</td>
    <td>Immediate</td>
    <td>Unknown</td>
    <td>Volume overload, hypertonicity</td>
  </tr>
  <tr>
  <td colspan="5"><b>REDISTRIBUTION</b></td>
  </tr>
  <tr>
    <td><span class="drug">Insulin</span></td>
    <td>10 units IVP with D50W</td>
    <td>20 min</td>
    <td>4-6 hr</td>
    <td>Hypoglycemia</td>
  </tr>
  <tr>
    <td><span class="drug">Albuterol nebulized</span></td>
    <td>20 mg/4 cc over 10 min</td>
    <td>30 min</td>
    <td>2 hrs</td>
    <td>Tachycardia</td>
  </tr>
  <tr>
  <td colspan="5"><b>ELIMINATION</b></td>
  </tr>
  <tr>
    <td><span class="drug">Loop diuretic</span></td>
    <td>Furosemide 40-80 mg IV</td>
    <td>15 min</td>
    <td>2-3 hr</td>
    <td>Volume depletion</td>
  </tr>
  <tr>
    <td><span class="drug">Sodium bicarbonate</span></td>
    <td>150 mmol/L IV</td>
    <td>Hours</td>
    <td>Infusion</td>
    <td>Metabolic alkalosis, volume overload</td>
  </tr>
  <tr>
    <td><span class="drug">Kayexalate</span></td>
    <td>15-30 g</td>
    <td>>2 hrs</td>
    <td>4-6 hr</td>
    <td>Variable efficacy</td>
  </tr>
  <tr>
    <td><span class="drug">Hemodialysis</span></td>
    <td></td>
    <td>Immediate</td>
    <td>3 hrs</td>
    <td>Arrhythmias</td>
  </tr>
</table>

<h2 id="references">References</h2>
<ul>
<li>Weisberg LS. Management of severe hyperkalemia. <em>Crit Care Med</em>. 2008; 36:3246-51. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18936701">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"hyperkalemia","title":"Hyperkalemia","authors":["Michelle Lin, MD"],"categories":[{"slug":"endocrinology","name":"Endocrinology"},{"slug":"metabolic","name":"Metabolic"},{"slug":"critical-care","name":"Critical Care"}],"created":"2010/03/12","updated":null,"body":"\n# Hyperkalemia\n\n## Potassium regulation\n\n- **Internal K shift:** modulated by insulin, catecholamines, acid-base status\n- **Total body K elimination:** By kidney (95%) and gut (5%)\n\n## Adverse effects of hyperkalemia\n\n- **Cardiac:** Peaked T, wide QRS, loss of P wave, sine wave; although ventricular fibrillation may be first cardiac manifestation\n- **Neuromuscular:** Paresthesias,weakness\n- **Metabolic:** Mild hyperchloremic metabolic acidosis\n\n## Treatment of hyperkalemia\n\n**Mechanism: Cardiac membrane stabilization**\n\n- **Calcium:** Reduces threshold potential in myocytes; check to be sure not on digoxin\n- **Hypertonic saline:** Only for severe hyponatremia in setting of hyperkalemia\n\n**Mechanism: K redistribution**\n\n- **Insulin:** Drives K intracellularly and drops serum K level by 0.6 mmol/L\n- **Beta-agonist:** Drives K intracellularly and 10 mg albuterol drops serum K level by 0.6 mmol/L (20 mg --\u003e K drops by 1 mmol/L); effective in only 60% of patients\n\n**Mechanism: K elimination via kidney/gut**\n\n- **Bicarbonate:** drives K out at distal nephron; best as infusion x 4-6 hrs\n- **Loop diuretic**\n- **Exchange resin** (sodium polystyrene sulfonate): Of minimal to no benefit. \n  - Case reports of colonic necrosis \n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eAgent\u003c/th\u003e\n    \u003cth\u003eDose\u003c/th\u003e\n    \u003cth\u003eOnset\u003c/th\u003e\n    \u003cth\u003eDuration\u003c/th\u003e\n    \u003cth\u003eComplication\u003c/th\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd colspan=\"5\"\u003e\u003cb\u003eMEMBRANE STABILIZATION\u003c/b\u003e\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cspan class=\"drug\"\u003eCa gluconate 10%\u003c/span\u003e\u003c/td\u003e\n    \u003ctd\u003e10 mL over 10 min\u003c/td\u003e\n    \u003ctd\u003eImmediate\u003c/td\u003e\n    \u003ctd\u003e30-60 min\u003c/td\u003e\n    \u003ctd\u003eHypercalcemia\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cspan class=\"drug\"\u003eHypertonic 3% NaCl\u003c/span\u003e\u003c/td\u003e\n    \u003ctd\u003e50 mL IV push\u003c/td\u003e\n    \u003ctd\u003eImmediate\u003c/td\u003e\n    \u003ctd\u003eUnknown\u003c/td\u003e\n    \u003ctd\u003eVolume overload, hypertonicity\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n  \u003ctd colspan=\"5\"\u003e\u003cb\u003eREDISTRIBUTION\u003c/b\u003e\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cspan class=\"drug\"\u003eInsulin\u003c/span\u003e\u003c/td\u003e\n    \u003ctd\u003e10 units IVP with D50W\u003c/td\u003e\n    \u003ctd\u003e20 min\u003c/td\u003e\n    \u003ctd\u003e4-6 hr\u003c/td\u003e\n    \u003ctd\u003eHypoglycemia\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cspan class=\"drug\"\u003eAlbuterol nebulized\u003c/span\u003e\u003c/td\u003e\n    \u003ctd\u003e20 mg/4 cc over 10 min\u003c/td\u003e\n    \u003ctd\u003e30 min\u003c/td\u003e\n    \u003ctd\u003e2 hrs\u003c/td\u003e\n    \u003ctd\u003eTachycardia\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n  \u003ctd colspan=\"5\"\u003e\u003cb\u003eELIMINATION\u003c/b\u003e\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cspan class=\"drug\"\u003eLoop diuretic\u003c/span\u003e\u003c/td\u003e\n    \u003ctd\u003eFurosemide 40-80 mg IV\u003c/td\u003e\n    \u003ctd\u003e15 min\u003c/td\u003e\n    \u003ctd\u003e2-3 hr\u003c/td\u003e\n    \u003ctd\u003eVolume depletion\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cspan class=\"drug\"\u003eSodium bicarbonate\u003c/span\u003e\u003c/td\u003e\n    \u003ctd\u003e150 mmol/L IV\u003c/td\u003e\n    \u003ctd\u003eHours\u003c/td\u003e\n    \u003ctd\u003eInfusion\u003c/td\u003e\n    \u003ctd\u003eMetabolic alkalosis, volume overload\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cspan class=\"drug\"\u003eKayexalate\u003c/span\u003e\u003c/td\u003e\n    \u003ctd\u003e15-30 g\u003c/td\u003e\n    \u003ctd\u003e\u003e2 hrs\u003c/td\u003e\n    \u003ctd\u003e4-6 hr\u003c/td\u003e\n    \u003ctd\u003eVariable efficacy\u003c/td\u003e\n  \u003c/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cspan class=\"drug\"\u003eHemodialysis\u003c/span\u003e\u003c/td\u003e\n    \u003ctd\u003e\u003c/td\u003e\n    \u003ctd\u003eImmediate\u003c/td\u003e\n    \u003ctd\u003e3 hrs\u003c/td\u003e\n    \u003ctd\u003eArrhythmias\u003c/td\u003e\n  \u003c/tr\u003e\n\u003c/table\u003e\n\n## References\n\n- Weisberg LS. Management of severe hyperkalemia. _Crit Care Med_. 2008; 36:3246-51. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18936701)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"hyperkalemia"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>